U.S. Markets open in 37 mins
  • S&P Futures

    3,649.00
    -11.50 (-0.31%)
     
  • Dow Futures

    29,666.00
    -138.00 (-0.46%)
     
  • Nasdaq Futures

    12,400.00
    -52.25 (-0.42%)
     
  • Russell 2000 Futures

    1,826.50
    -9.00 (-0.49%)
     
  • Crude Oil

    44.46
    -0.09 (-0.20%)
     
  • Gold

    1,822.00
    +3.10 (+0.17%)
     
  • Silver

    23.97
    -0.12 (-0.52%)
     
  • EUR/USD

    1.2079
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    0.9360
    +0.0020 (+0.21%)
     
  • Vix

    21.10
    +0.53 (+2.58%)
     
  • GBP/USD

    1.3301
    -0.0122 (-0.9098%)
     
  • USD/JPY

    104.5920
    +0.2760 (+0.2646%)
     
  • BTC-USD

    19,135.81
    +141.91 (+0.75%)
     
  • CMC Crypto 200

    375.14
    -4.72 (-1.24%)
     
  • FTSE 100

    6,405.73
    +21.00 (+0.33%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Why NovaBay's Stock Is Trading Lower Today

Tanzeel Akhtar
·1 min read

NovaBay Pharmaceuticals (NYSE: NBY) shares are trading lower on Tuesday after the company received an FDA warning letter for misleading claims regarding Avenova in COVID-19.

NovaBay Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eye care market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox).

The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets.

NovaBay Pharmaceuticals shares were trading down 14.47% at 52 cents on Tuesday. The stock has a 52-week high of $1.94 and a 52-week low of 24 cents.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.